Literature DB >> 9096641

HLA class-I-restricted and tumor-specific CTL in tumor-infiltrating lymphocytes of patients with gastric cancer.

T Hoshino1, N Seki, M Kikuchi, T Kuramoto, O Iwamoto, I Kodama, K Koufuji, J Takeda, K Itoh.   

Abstract

Immune recognition of human cancers except melanoma is not well understood at either the cellular or the molecular level. We demonstrate in this study the existence of HLA class-I-restricted and tumor-specific CTL in IL-2-activated TIL (tumor-infiltrating lymphocytes) of all 4 gastric cancer patients tested. We established HLA A2-restricted and adenocarcinoma-specific CTL in 2 HLA A0201+ patients, and HLA A2402-restricted CTL recognizing both adenocarcinoma and squamous-cell carcinomas (SCC) in the 2 remaining HLA A2402+ patients. Further, HLA A3101-restricted and adenocarcinoma-specific CTL were established in 1 of the 2 HLA A2402+ patients who had HLA A3101 allele. HLA A2-, A2402- and A3101-restricted CD8+ CTL clones were established from these parental CTL lines. The 2 HLA A2-restricted CTL lines lysed 8 of 13 HLA A2+ adenocarcinoma cell lines established from different organs (stomach, colon, lung and breast) with different subtypes (HLA A0201, A0206 and A0207). The HLA A2-restricted CTL line recognized 9 and 6 different HPLC fractions of peptides eluted from the HLA A0201+ breast and HLA A0201+ colon adenocarcinoma cell lines, respectively. Allele-specific deletion of HLA A2 or A24 molecules was observed in some tumor lines that were not susceptible to lysis by the CTL lines. These results suggest that TIL of gastric cancer possess CTL recognizing different peptide antigens binding to different HLA-A alleles that are widely expressed on adenocarcinomas and also, to some extent, on SCC from different organs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9096641     DOI: 10.1002/(sici)1097-0215(19970317)70:6<631::aid-ijc1>3.0.co;2-w

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  18 in total

1.  An increased number of PD-1+ and Tim-3+ CD8+ T cells is involved in immune evasion in gastric cancer.

Authors:  Shuichi Takano; Hiroaki Saito; Masahide Ikeguchi
Journal:  Surg Today       Date:  2016-01-22       Impact factor: 2.549

2.  HLA class-I-restricted and colon-specific cytotoxic T cells from lamina propria lymphocytes of patients with ulcerative colitis.

Authors:  T Sunagawa; Y Yonamine; F Kinjo; M Watanabe; T Hibi; A Saito
Journal:  J Clin Immunol       Date:  2001-11       Impact factor: 8.317

3.  Co-inhibition of TIGIT, PD1, and Tim3 reverses dysfunction of Wilms tumor protein-1 (WT1)-specific CD8+ T lymphocytes after dendritic cell vaccination in gastric cancer.

Authors:  Xu Lu; Jingwei Liu; Peilin Cui; Tao Liu; Chunmei Piao; Xianghong Xu; Qike Zhang; Man Xiao; Xuesong Liu; Yue Wang; Lin Yang
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

4.  Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer.

Authors:  M W Bennett; J O'connell; G C O'sullivan; D Roche; C Brady; J Kelly; J K Collins; F Shanahan
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

5.  Decreased Serum Concentration of Total IgG Is Related to Tumor Progression in Gastric Cancer Patients.

Authors:  Hiroaki Saito; Kozo Miyatani; Yusuke Kono; Yuki Murakami; Hirohiko Kuroda; Tomoyuki Matsunaga; Yoji Fukumoto; Shuichi Takano; Tomohiro Osaki; Yoshiyuki Fujiwara
Journal:  Yonago Acta Med       Date:  2017-06-26       Impact factor: 1.641

Review 6.  Gastric cancer and the epoch of immunotherapy approaches.

Authors:  Elena Niccolai; Antonio Taddei; Domenico Prisco; Amedeo Amedei
Journal:  World J Gastroenterol       Date:  2015-05-21       Impact factor: 5.742

7.  A high number of IgG4-positive cells in gastric cancer tissue is associated with tumor progression and poor prognosis.

Authors:  Kozo Miyatani; Hiroaki Saito; Yuki Murakami; Joji Watanabe; Hirohiko Kuroda; Tomoyuki Matsunaga; Yoji Fukumoto; Tomohiro Osaki; Yuji Nakayama; Yoshihisa Umekita; Masahide Ikeguchi
Journal:  Virchows Arch       Date:  2016-03-07       Impact factor: 4.064

8.  Increased B7-H1 and B7-H4 Expressions on Circulating Monocytes and Tumor-Associated Macrophages are Involved in Immune Evasion in Patients with Gastric Cancer.

Authors:  Tomoyuki Matsunaga; Hiroaki Saito; Masahide Ikeguchi
Journal:  Yonago Acta Med       Date:  2011-03-01       Impact factor: 1.641

Review 9.  Adoptive-cell-transfer therapy for the treatment of patients with cancer.

Authors:  Mark E Dudley; Steven A Rosenberg
Journal:  Nat Rev Cancer       Date:  2003-09       Impact factor: 60.716

10.  Molecular cancer vaccines: Tumor therapy using antigen-specific immunizations.

Authors:  T Schweighoffer
Journal:  Pathol Oncol Res       Date:  1997-09       Impact factor: 2.874

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.